Ketamine's Bipolar Balancing Act

Bipolar depression creates an agonizing clinical trap: patients are paralyzed by severe lows, yet traditional antidepressants take weeks to work and carry the terrifying risk of an "affective switch"—triggering a manic episode or rapid cycling. In Episode 55, we explore a 2026 review by Queissner and colleagues showing how ketamine and esketamine rewrite the rules by bypassing serotonin and targeting the brain's glutamate "gas pedal". We unpack the staggering data: an odds ratio of 10.68 for rapid relief, with the REAL-ESK study showing zero cases of manic switching in real-world patients using intranasal esketamine. The episode dives deep into the biology, exploring Rizzo's 2025 discovery of ketamine's dual mechanism (NMDA and mu-opioid receptor modulation) that specifically targets anhedonia by restoring dopamine to the brain's reward center. Finally, we discuss why ketamine isn't a solo act—and how foundational mood stabilizers like lithium act as a safety net that synergizes with ketamine to spark central neuroplasticity and structural brain repair. Reference: Queissner, R., Fellendorf, F., & Reininghaus, E. Z. (2026). Ketamine as an NMDA-modulating therapy in bipolar disorder: Rationale and evidence. Frontiers in Psychiatry, 17, 1777402. https://doi.org/10.3389/fpsyt.2026.1777402